PEAK6 Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

PEAK6 Investments’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-800	Closed	-$287K	–	4224
2023 Q3	$287K	Sell	800 -800	-50%	-$309K	﹤0.01%	2817
2023 Q2	$607K	Buy	1,600 +1,500	+1,500%	+$610K	﹤0.01%	2057
2023 Q1	$47.9K	Buy	+100	New	+$46.8K	﹤0.01%	3758
2022 Q3	–	Sell	-1,600	Closed	-$607K	–	4998
2022 Q2	$607K	Sell	1,600 -2,000	-56%	-$1.04M	﹤0.01%	3613
2022 Q1	$2.03M	Sell	3,600 -3,600	-50%	-$2.17M	﹤0.01%	1837
2021 Q4	$5.44M	Sell	7,200 -1,700	-19%	-$1.27M	0.01%	1074
2021 Q3	$6.64M	Buy	8,900 +7,100	+394%	+$5.32M	0.01%	960
2021 Q2	$1.16M	Buy	1,800 +1,300	+260%	+$791K	﹤0.01%	2417
2021 Q1	$286K	Sell	500 -2,000	-80%	-$1.18M	﹤0.01%	3668
2020 Q4	$1.46M	Sell	2,500 -5,600	-69%	-$3.19M	﹤0.01%	2125
2020 Q3	$4.17M	Buy	8,100 +6,500	+406%	+$3.29M	0.01%	1080
2020 Q2	$722K	Buy	1,600 +900	+129%	+$397K	﹤0.01%	2377
2020 Q1	$245K	Sell	700 -5,300	-88%	-$1.95M	﹤0.01%	2673
2019 Q4	$2.22M	Buy	+6,000	New	+$2.12M	0.01%	1023
2018 Q4	–	Sell	-4,900	Closed	-$1.53M	–	4008
2018 Q3	$1.53M	Buy	+4,900	New	+$1.52M	0.01%	1646

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PEAK6 Investments's BIO Position: Q3 2024 in Review

PEAK6 Investments opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2024: 2,857 shares worth $956K. The stake represents ﹤0.01% of the portfolio and ranks #1938 among its holdings. This is a return to the name: PEAK6 Investments previously reported a position in BIO as recently as Q1 2024.

PEAK6 Investments first reported a position in BIO in Q3 2018 and has held it in 16 quarters since. The position peaked at $1.52M in Q4 2021. 437 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

PEAK6 Investments held 2,857 shares of Bio-Rad Laboratories Class A worth $956K as of Q3 2024.
Bio-Rad Laboratories Class A was a new PEAK6 Investments position in Q3 2024.
Bio-Rad Laboratories Class A made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #1938 holding.
PEAK6 Investments first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and has held it in 16 quarters since.
PEAK6 Investments's Bio-Rad Laboratories Class A position peaked at $1.52M in Q4 2021.
437 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.